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A B S T R A C T
All individuals with Down syndrome (DS), which results from trisomy of human chromosome 21 (Ts21), present
with skeletal abnormalities typified by craniofacial features, short stature and low bone mineral density (BMD).
Differences in skeletal deficits between males and females with DS suggest a sexual dimorphism in how trisomy
affects bone. Dp1Tyb mice contain three copies of all of the genes on mouse chromosome 16 that are homo-
logous to human chromosome 21, males and females are fertile, and therefore are an excellent model to test the
hypothesis that gene dosage influences the sexual dimorphism of bone abnormalities in DS. Dp1Tyb as compared
to control littermate mice at time points associated with bone accrual (6 weeks) and skeletal maturity (16 weeks)
showed deficits in BMD and trabecular architecture that occur largely through interactions between sex and
genotype and resulted in lower percent bone volume in all female and Dp1Tyb male mice. Cortical bone in
Dp1Tyb as compared to control mice exhibited different changes over time influenced by sex × genotype in-
teractions including reduced cortical area in both male and female Dp1Tyb mice. Mechanical testing analyses
suggested deficits in whole bone properties such as bone mass and geometry, but improved material properties
in female and Dp1Tyb mice. Sexual dimorphisms and the influence of trisomic gene dosage differentially altered
cellular properties of male and female Dp1Tyb bone. These data establish sex, gene dosage, skeletal site and age
as important factors in skeletal development of DS model mice, paving the way for identification of the causal
dosage-sensitive genes. Skeletal differences in developing male and female Dp1Tyb DS model mice replicated
differences in less-studied adolescents with DS and established a foundation to understand the etiology of tri-
somic bone deficits.
1. Introduction
Trisomy 21 (Ts21) affects ~1/800 live births and results in dis-
tinctive craniofacial features and skeletal deficits, including short sta-
ture in all individuals with Down syndrome (DS). Alterations in skeletal
features associated with DS begin prenatally and continue postnatally;
adolescents exhibit low bone accrual during puberty, and adults have
documented bone loss [1–3]. Fetuses with Ts21 are often characterized
ultrasonically with a short femur and humerus, but these soft markers
are not diagnostic [4–7]. At birth, infants with DS are shorter than ty-
pically developing individuals [8,9] and on average, this reduced
height continues throughout life [2]. The short stature caused by Ts21
is related to a delay in the development of the secondary centers of
ossification and final peak height reached around the age of 15 [1,10].
Peak bone mass is reached ~5–10 years earlier than normal and is
lower in individuals with DS as compared to the general population
[11]. This predisposition to weaker and shorter bones in people with
Ts21, through attenuated bone accrual or altered organization, may be
exacerbated due to hypotonia, hormonal and nutritional deficits,
growth retardation, low muscle strength and reduced physical activity
[12–14].
Therapeutic advancements have brought average expected DS life-
span up to ~60 years [15–17], but individuals with DS are thus in-
creasingly at risk for low bone mineral density (BMD) and fractures.
Skeletal deficiencies and lack of bone mass accrual during development
predispose people with Ts21 to fragility fractures, and at later ages,
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osteoporosis [2,13,18,19]. All people with DS are at risk for osteo-
porosis and osteopenia [10,20,21]; and a high percentage of individuals
with DS have suffered fractures [22,23]. Though the risk for osteo-
porosis is higher in adults with intellectual disabilities, the overall bone
density screening rates are lower in these same individuals [24]. In-
dividuals with DS exhibit many hallmarks associated with osteoporosis
including a lower BMD, altered geometry, and reduced overall strength.
These skeletal deficits found in DS are not only age- and sex-dependent,
like normally developing individuals, but are also influenced by having
three copies of the genes on human chromosome 21 (Hsa21). Because
of the known skeletal abnormalities in all people with DS and the in-
creasing age in the same population, there is a critical need to address
the etiology of these skeletal abnormalities.
Some differences in bone properties between males and females
with Ts21 have been observed, but low sample sizes, variety of analysis
methods, wide array of ages, different skeletal measurement sites makes
comparisons between studies difficult [23]. Thus the etiology of DS
sexual dimorphism remains unclear. Adolescent females with DS are
hypothesized to acquire BMD at a lower rate compared to adolescent
males with DS [2,3]. BMD is decreased in the lumbar spine of
12–16 year old males and females (analyzed together) with DS com-
pared to age matched adolescents [25]. Twenty adolescents with DS
(males and females analyzed together) compared to 20 males and fe-
males without DS showed a lower BMD in lumbar spine, hip, and whole
body [26]. However, no differences were seen in femur BMD between
males and females with Ts21 in a study of 12 male and 14 female
adolescents with DS [27]. When the lumbar vertebrate of males and
females (average age ~25 years) with and without DS were analyzed,
males with DS as compared to controls had 25% lower BMD and fe-
males with DS had 14% lower BMD [1]. Males with Ts21 have been
reported to have greater BMD and bone area in the upper and lower
limbs than females with DS [2]. Additionally, osteopenia has been re-
ported to occur earlier in males with DS [28], and unlike the most
common forms of osteoporosis where 80% of the affected individuals
are women, osteoporosis affects both men and women with Ts21. Dif-
ferences in calculations of BMD using T- or Z-scores to determine a low
bone mass or osteoporosis add to the variation and bias in individuals
with DS [23].
Recent publications detail skeletal deficiencies across life stages in
males and females with DS in larger sample sizes and compared to
normal developing populations. When femoral neck and lumbar spine
BMD were measured in adult males and females with Ts21 ages 20–69,
both males and females with DS as compared to reference samples
showed lower lumbar spine and femoral neck BMD throughout their
lives [14,29]. Males with DS had reduced femoral neck BMD beginning
in their 20s but females with DS did not show reduced femoral neck
BMD until their 40s. When 128 adults with DS were compared to age-
matched adults without DS and other intellectual disabilities, lumbar
spine BMD in men was relatively stable in early to mid-adulthood, and
bone mineral accrual was later in women than men with DS [30].
Women with DS also saw a rapid loss of bone mass after age 40. Both
men and women with DS had higher rates of osteopenia and osteo-
porosis than a reference population. Taken together, these data indicate
different skeletal deficits seen in males and females with DS, but they
are complex in their nature, and not well defined in relation to age,
skeletal site, and fracture risk.
Mouse models recapitulate the genetic (trisomy) and phenotypic
(DS-associated traits) features attributed to Ts21 [31–33] and are uti-
lized to understand skeletal phenotypes associated with DS. The Ts
(1716)65Dn mouse (Ts65Dn), the most widely used and well-char-
acterized mouse model of DS, has a small trisomic chromosome that
contains ~104 genes and 13 Mb that correspond to Hsa21 [34,35].
Adult Ts65Dn male mice show structural and biomechanical skeletal
deficits [36–38]. A significant increase in osteoclast surface and os-
teoclast number was observed in 6 week old Ts65Dn compared to wild-
type male mice [39]. Overall, studies in mice and humans imply that
trisomy causes developmental bone abnormalities, compromised bone
strength, and early onset osteoporosis due to a combination of altered
developmental, homeostatic and resorptive bone mechanisms
[36,37,39].
Though skeletal differences between normal and trisomic bone have
been established using DS mouse models, little has been done to ex-
amine the effect of sex on trisomic skeletal structure, mechanics, and
cellular composition, mostly because female Ts65Dn mice are reserved
for colony maintenance. Additionally, Ts65Dn mice contain three co-
pies of ~35 protein coding genes from mouse chromosome 17 (Mmu17)
that are orthologous to Hsa6 [32,40,41] and the contribution of these
genes to skeletal phenotypes is unknown. No differences in BMD were
seen at 3 or 16 weeks in male or female Ts1Rhr mice with trisomy for
33 orthologous Hsa21 genes (4.2 Mb), likely due to the ages sampled
and the limitations of the methodology used to characterize the skeletal
defects in these animals [42]. C57BL/6J.129P2-Dp(16Lipi-Zbtb21)
1TybEmcf/Nimr (Dp1Tyb) mice have a duplication on Mmu16 Lipi to
Zbtb21 spanning 23 Mb and 148 coding genes and contain three copies
of all of the genes on Mmu16 that are orthologous to Hsa21 [43]. Both
male and female Dp1Tyb mice are fertile which facilitates examination
of skeletal features of both sexes in this mouse model. We hypothesized
that Dp1Tyb male mice would have similar bone phenotypes as Ts65Dn
male mice and that female mice would have a distinct bone phenotype
as compared to male DS mice, which will establish a sexually dimorphic
phenotype in the appendicular skeleton of a novel DS mouse model.
Additionally, we hypothesized bone abnormalities would be differen-
tially affected during longitudinal growth periods of bone accrual and
the onset of skeletal maturity.
2. Materials and methods
2.1. Animals
C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb)
mice [43] were bred at the Medical Research Council (MRC) Harwell
Institute, UK by crossing to C57BL/6J mice. Genotyping was under-
taken using custom probes (Transnetyx). Female mice were nulliparous.
Femurs were isolated from Dp1Tyb and littermate wild-type mice at 6
and 16 weeks of age. Right femurs were stored in phosphate buffered
saline (PBS)-soaked gauze, shipped on dry ice and stored at −80 °C to
be used for microcomputed tomography (μCT) analysis and mechanical
testing. Left femurs were stored in 70% ethanol and analyzed for dy-
namic and static histomorphometry. From our previous skeletal ana-
lyses, we estimated that we would need ten mice of each genotype to
quantify both trabecular and cortical bone parameters (α = 0.05, 1-
β = 0.80 in power analyses). Femurs from 6-week-old male (n = 10
control, n = 10 Dp1Tyb) and female (n = 12 control, n = 11 Dp1Tyb);
and 16-week-old male (n = 13 control, n = 12 Dp1Tyb) and female
(n = 19 control, n = 22 Dp1Tyb) were used. All assessment of femurs
was done with investigators blind to sample genotype. Histomorpho-
metry was only completed on 16-week-old male and female mice. All
regulated procedures were carried out with approval from a Local
Ethical Review Panel and under authority of a Project License granted
by the UK Home Office, and in accordance with EU Directive 2010/63/
EU.
2.2. Preliminary skeletal analysis
DEXA was performed on Dp1Tyb and control mice at 14 weeks as
described in https://www.mousephenotype.org/impress/protocol/90/
7. Each X-ray image included a standard measurement of 20 mm.
Femur (measured from proximal epiphysis to distal epiphysis) and
rostrocaudal (tip of the soft tissue of the nose to base of tail) lengths
were measured via ImageJ. The femur was analyzed due to its pre-
valence in the Jackson Laboratory Phenome database and previous
work in DS mouse models.
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2.3. Microcomputed tomography (μCT) analysis
Femurs were thawed to room temperature and scanned using high-
resolution μCT system, SkyScan 1172 microCT (SkyScan, Kontich,
Belgium) using the following parameters: voltage 60 kV, 12 μM nom-
inal voxel size, binning mode 2 k and filter Al 0.5 mm. Calibrations
were performed daily using two cylindrical hydroxyapatite phantoms
(0.25 and 0.75 g/cm3 calcium hydroxyapatite). Femurs were re-
wrapped in PBS-soaked gauze and stored at −80 °C until mechanical
testing. Reconstruction analysis was performed using NRecon and CTan
software (Skyscan, Bruker microCT, Belgium). Trabecular and cortical
analyses were accomplished using previously published protocol
[44,45].
Trabecular analysis was performed on the distal metaphysis with a
region of interest (ROI) defined as 10% of the total bone length, ap-
proximately 1 mm proximal to the distal growth plate and then ex-
tending proximally. The ROI was auto-segmented using a custom
Matlab (MathWorks, Inc. Natick, MA) code [45]. Measurements of
trabecular architecture (bone volume fraction [BV/TV], trabecular
thickness, number, and separation), bone mineral density (BMD), and
tissue mineral density (TMD) were calculated using CTAn.
Cortical analysis was performed at a standard site 60% of the total
bone length away from the distal growth plate. Seven transverse slices
were generated from the standard site and cortical geometric properties
were obtained from using a custom Matlab code.
2.4. Mechanical testing
The mechanical properties of the femur were determined by 3-point
bending using a mechanical testing machine (TA ElectroForce 3200;
Eden Prairie, MN, USA). The femurs were thawed to room temperature
and tested in the anterior-posterior direction with the posterior surface
in compression (7 mm support span). The load was applied to the
midpoint of each bone. The femur was preloaded using 0.5 N to es-
tablish contact with the bone and then monotonically tested to failure
at a displacement rate of 0.025 mm/s while fully hydrated. Load and
deflection were recorded, from which structural strength (yield and
ultimate), stiffness (slope of the linear portion of the force versus dis-
placement curve), and deformation (yield deformation, postyield de-
formation and total deformation) were determined [46,47]. Distance
from the proximal end of the femur to the location of the fracture in-
itiation was measured using calipers. Seven transverse slices were ob-
tained from μCT at the location of fracture and calculated geometric
properties (bending moment of inertia and distance from the centroid
to the tensile surface of the bone). Along with the deflection data, the
moment of inertia and distance from the centroid to the tensile surface
of the bone in tension derived were used to map load-displacement into
stress vs. strain curves using standard equations derived from Euler-
Bernoulli beam theory to estimate tissue level properties [46]. The
mechanical strength, stiffness, and work/toughness were determined












In these equations, F is the force, d is the displacement, a is the
distance from the support to the inner loading point (4 mm), and L is
the span between the outer supports (7 mm). The yield point was cal-
culated using the 0.2% offset method based on the stress-strain curve.
The modulus of elasticity was calculated as the slope of the linear
portion of the stress-strain curve.
2.5. Histomorphometric analyses
Male and female mice were injected intraperitoneally with 0.6%
Calcein green diluted in PBS at 15 weeks of age, and injected again
4 days later. Three days after the second injection of Calcein green, the
mice were euthanized and weighed (16 weeks of age). Femurs were
removed and placed in 70% ethanol and stored at room temperature
until ready for use. The femur was separated at the midshaft and the
proximal and distal femurs were processed, cut, and sectioned as de-
scribed [36]. Briefly, femurs were dehydrated in graded levels of
ethanol, cleared in xylene and embedded in methyl methacrylate. For
dynamic histology, the midshaft of the femur was sectioned into
500 μm transverse sections and ground to 40 μm and then mounted
using Eukitt to enhance viewing of fluorescent label. One section was
read using a D-FL Epi-Fluorescence attachment on a Nikon Eclipse 80i
DIC microscope, and images were taken using a Nikon DS-Fi1 digital
sight camera. Mineralizing surface/bone surface (MS/BS) was assessed
by measuring the double label surface (dL.S), single label surface (sL.S),
and total bone surface (BS) using BioQuant software (R & M Biometrics,
Nashville, TN; MS/BS = (dL.S. + 0.5 ∗ sL.S)/BS). Mineral apposition
rate (MAR) was determined by measuring the average interlabel width
between two fluorochrome labels using the Bioquant software, divided
by the number of days between label administration. MS/BS and MAR
were used to quantify bone formation rate (BFR=MS/BS ∗ MAR ∗ 365;
μm3/μm2/year). Based on the measurements obtained from dynamic
labeling, some mice had to be removed from analysis: for the periosteal
surface 16-week-old male (n = 9 wild-type, n = 7 Dp1Tyb) and female
(n = 9 wild-type, n = 9 Dp1Tyb) were used. For the endocortical
surface, 16-week-old male (n = 10 wild-type, n = 8 Dp1Tyb) and fe-
male (n = 11 wild-type, n = 10 Dp1Tyb) were used.
For the static histomorphometry, sections of the distal femur were
deplasticsized in acetone and stained for osteoid using the Von Kossa-
MacNeal's tetrachrome protocol or osteoclasts using TRAP staining.
Osteoclast surface to bone surface (OcS/BS), osteoclast number per
1 mm tissue (Oc#/BS), and osteoid surface/bone surface (OS/BS) were
quantified using Bioquant software. Sixteen-week-old male (n = 13
control, n = 10 Dp1Tyb) and female (n = 11 control, n = 12 Dp1Tyb)
were used for osteoclast analysis and 16-week-old male (n = 13 con-
trol, n = 11 Dp1Tyb) and female (n = 13 control, n = 12 Dp1Tyb)
were used for osteoid analysis.
2.6. Statistical tests
MicroCT and mechanical testing data were analyzed using a custom
Matlab code [45]. For microCT, mechanical testing, and histomorpho-
metry data, normality and homogeneity were assessed for each phe-
notype and any violations were transformed to achieve normality. To
control for the analysis of multiple dependent variables, separate
MANOVAs (Wilks' Lambda, IBM SPSS version 26) were performed on
the 6- and 16-week-old mice for trabecular (4 parameters), cortical (14
parameters) and mechanical (16 parameters) data. If the MANOVA for a
given age and bone type yielded significant main or interactive effects
of genotype and/or sex, follow-up 2-way factorial ANOVAs were per-
formed on each individual parameter to identify which of the individual
parameters expressed the main (or interactive) effects that were sig-
nificant in the MANOVA. If the MANOVA yielded no significant effects,
no additional follow-up analyses were performed. Effect sizes were
obtained from the SPSS calculations of partial eta squared in each
ANOVA. For each parameter with a significant interaction, post hoc
analyses (Tukey's multiple comparisons test) determined differences
between groups.
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3. Results
3.1. Preliminary skeletal analyses
Preliminary analyses on mice at 14 weeks showed an effect of both
sex (p < 0.001) and genotype (trisomy or extra gene dosage) on the
length from nose to base of tail (p = 0.001) (Dp1Tyb male = 89.84
(SE ± 0.86) mm; control male = 93.12 (0.94) mm; Dp1Tyb fe-
male = 85.24 (1.15) mm; control female = 88.56 (0.41) mm; n = 10
for all samples). Male and control mice overall showed a longer body at
14 weeks. The length of the femur was greater in wild-type mice as
compared to Dp1Tyb mice at 14 weeks (p < 0.001) (Dp1Tyb
male = 14.78 (0.20) mm; control male = 15.72 (0.20) mm; Dp1Tyb
female = 14.76 (0.22); control female = 15.40 (0.18); n = 10 for all
samples).
3.2. Interaction of sex and genotype in Dp1Tyb mice alters BV/TV during
skeletal maturation
The interaction of sex (male vs. female) and genotype (three copy
vs. normal copy number) was important in percent bone volume (bone
volume/tissue volume or BV/TV) at both 6 and 16 weeks of age. At
6 weeks of age during longitudinal bone growth, BV/TV was reduced in
male Dp1Tyb, female Dp1Tyb and female control animals as compared
to male control animals (Fig. 1A). At 16 weeks of age, a time of skeletal
maturity, BV/TV continued to be reduced in male Dp1Tyb, female
Dp1Tyb and female control animals as compared to male control ani-
mals. Additionally, female Dp1Tyb mice had reduced BV/TV as
compared to male Dp1Tyb mice (Fig. 1A). BV/TV increased in male
mice from 6 to 16 weeks of age (p < 0.001), but female mice exhibited
a loss in BV/TV during the same time period (p = 0.025). Similar data
were observed for BMD in the trabecular compartment at both 6 and
16 weeks. Taken together, these data indicate that percent bone volume
is reduced in Dp1Tyb as compared to wild-type male mice as the bone is
actively growing, and approximately when skeletal maturity is
achieved. Female mice have reduced formation or bone accrual in-
dependent of genotype at 6 weeks. At 16 weeks of age, as the appen-
dicular skeleton reaches skeletal maturity, BV/TV is increased in male
mice, but decreased in female mice as compared to 6 weeks of age.
3.3. Interaction between sex and genotype affects trabecular
microarchitecture in male and female Dp1Tyb and wild-type mice
Measurements of other trabecular skeletal parameters provide in-
sight into the interaction between sex and genotype. Trabecular number
(Tb.N) is increased in male wild-type mice compared to female Dp1Tyb
and wild-type mice at 6 and 16 weeks (Fig. 1B) and trabecular thickness
(Tb.Th) is greater in male wild-type mice than male and female Dp1Tyb
and wild-type mice at both 6 and 16 weeks (Fig. 1C). Trabecular se-
paration (Tb.Sp) is greater in female than male mice at 16 weeks
(Fig. 1D). In male mice, Tb.N increased (p = 0.013) and Tb.Sp de-
creased (p = 0.034) from 6 to 16 weeks for both genotypes. Tb.Th
showed an age × genotype interaction (p = 0.021) in male mice. When
only female mice were analyzed together at 6 and 16 weeks, Tb.N de-
creased and Tb.Th and Tb.Sp increased (p < 0.001 for all). These data
together imply that both male control and Dp1Tyb mice develop
Fig. 1. Trabecular measures on Dp1Tyb and littermate control femurs at 6 and 16 weeks (mean± SEM). MANOVAs on the combined four trabecular parameters,
performed separately for the 6- and 16-week data, respectively, indicated significant sex × genotype interactive effects (p = 0.001, p = 0.001), along with
significant main effects of sex (p < 0.001, p < 0.001) and genotype (p < 0.001, p = 0.003). The individual parameters are depicted in the four panels: (A)
Percent bone volume (BV/TV); 6 weeks: sex × genotype interaction: p = 0.044, [ηp2 = 0.103]; genotypic effect: p = 0.001, [ηp2 = 0.275], and sex effect:
p < 0.001, [ηp2 = 0.426]; 16 weeks: sex × genotype interaction: p = 0.001, [ηp2 = 0.164]; genotypic effect: p = 0.069, [ηp2 = 0.056], and sex effect: p < 0.001,
ηp2 = 0.785. (B) Trabecular number (Tb.N): 6 weeks: sex × genotype interaction: p < 0.001, [ηp2 = 0.268]; genotypic effect: p = 0.097, [ηp2 = 0.071], and sex
effect: p = 0.003, [ηp2 = 0.209]; 16 weeks: sex × genotype interaction: p = 0.009, [ηp2 = 0.112]; genotypic effect: p = 0.345, [ηp2 = 0.015], and sex effect:
p < 0.001, ηp2 = 0.779. (C) Trabecular thickness (Tb.Th): 6 weeks: sex × genotype interaction: p < 0.001, [ηp2 = 0.283]; genotypic effect: p < 0.001,
[ηp2 = 0.413], and sex effect: p < 0.001, [ηp2 = 0.446]; 16 weeks: sex × genotype interaction: p = 0.015, [ηp2 = 0.097]; genotypic effect: p = 0.021,
[ηp2 = 0.089], and sex effect: p < 0.001, [ηp2 = 0.420]. (D) Trabecular separation (Tb.Sp): 6 weeks: sex × genotype interaction: p = 0.174, [ηp2 = 0.048];
genotypic effect: p = 0.431, [ηp2 = 0.016], and sex effect: p = 0.063, [ηp2 = 0.088]; 16 weeks: sex × genotype interaction: p = 0.098, [ηp2 = 0.046]; genotypic
effect: p = 0.669, [ηp2 = 0.003], and sex effect: p < 0.001, [ηp2 = 0.736]. Male control (n = 10 6 wk.; n = 13 16 wk); Male Dp1Tyb; n = 10 6 wk.; n = 11 16 wk);
Female control (n = 12 6 wk.; n = 22 16 wk); Female Dp1Tyb (n = 10 6 wk.; n = 16 16 wk). Significant differences and interactions for individual parameters are as
determined by ANOVA and the p value is followed by partial eta squared [ηp2] as a measure of effect size. Similarities and differences between individual groups are
determined from Tukey's multiple comparisons post hoc tests; values with the same superscript letter are not significantly different. Letters a,b,c,d are used for
comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals.
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trabecular bone between 6 and 16 weeks consistent with a normal
growth pattern, however Dp1Tyb mice exhibit structural deficits com-
pared to control mice. Female mice gain Tb.Th and Tb.Sp and lose Tb.N
over time, indicating reduced bone modeling or increased resorption
across ages.
3.4. Cortical bone parameters exhibit differences between sex and genotype
in Dp1Tyb and control mice at 6 weeks, and interactive effects at 16 weeks
Six week-old control male and female mice had a greater total cross-
sectional area (total CSA) in the cortical bone than Dp1Tyb male and
female mice (Fig. 2A). Total CSA increased from 6 to 16 weeks in male
(p < 0.001) but not female (p = 0.61) mice. At 16 weeks of age, total
CSA is larger in control male than all other mice, male Dp1Tyb as
compared to female Dp1Tyb mice, and female control as compared to
female Dp1Tyb mice.
The sexual dimorphism and effects of trisomic gene dosage in total
CSA were further understood by examining other cortical parameters.
At 6 weeks of age, all control as compared Dp1Tyb mice together had a
larger marrow area, cortical area, cortical thickness, periosteal bone
surface (Ps.BS), endosteal bone surface (Es.BS), Imax, and Imin. Male as
compared to female mice overall exhibited greater cortical area, Imax
and Imin (Table 1 & Fig. 2). In addition to a reduction in cortical
structural parameters, Dp1Tyb mice exhibited lower tissue mineral
density (TMD) compared to their wild-type counterparts.
At 16 weeks of age, male control mice had larger total CSA, cortical
area, Ps.BS, Es.BS and Imax compared to all other mice, with male mice
as a group with higher parameters compared to female mice, and fe-
male Dp1Tyb mice having the lowest measurements (Table 1 & Fig. 2).
Marrow area and Imin are greater in male control than all other mice,
and female control are greater than female Dp1Tyb mice for these same
parameters. Female mice as a group had reduced cortical thickness
compared to male mice. These data suggest that the smaller total CSA in
male Dp1Tyb as compared to control mice at 6 and 16 weeks is due to
reduced Ps.BS, Es.BS, cortical thickness and marrow area at both ages.
In female mice, total CSA appears unchanged and cortical area and
thickness is increased from 6 to 16 weeks with decreases in Es.BS and
marrow area.
3.5. Mechanical bone parameters exhibit a sexual dimorphism in extrinsic
bone properties in Dp1Tyb and control mice
The interactive effect and main effect of genotype were significant
when all mechanical parameters at 6 weeks were analyzed together by
MANOVA, and the sex effect was marginal (p = 0.100). Interactive,
sex, and genotype effects were all significant at 16 weeks when me-
chanical parameters were analyzed together by MANOVA. At 6 weeks
of age in the mechanical properties of extrinsic bone (properties based
on bone mass and geometry), the only sex × genotype interaction was
for stiffness, with male euploid mice having greater stiffness than all
other mice. Control as compared to Dp1Tyb mice at 6 weeks exhibited
higher yield force (bone undergoes permanent deformation), ultimate
Fig. 2. Cortical measures on Dp1Tyb and control femurs at 6 and 16 weeks (mean± SEM). MANOVAs on the combined 16 cortical parameters, performed separately
for the 6- and 16-week cortical data, respectively, indicated significant main effects of sex (p = 0.003, p < 0.01) and genotype (p < 0.001, p < 0.001). The
interaction between sex and genotype was significant at 16 weeks p = p < 0.001) but not 6 weeks (p = 0.236). Four of the 16 individual parameters showing
significant sex × genotype interactions at 16 weeks are depicted in the four panels: (A) Cortical total cross-sectional area (CSA): 6 weeks: sex × genotype interaction:
p = 0.024, [ηp2 = 0.127]; genotypic effect: p < 0.001, [ηp2 = 0.689], and sex effect: p = 0.014, [ηp2 = 0.149]; 16 weeks: sex × genotype interaction: p = 0.001,
[ηp2 = 0.177]; genotypic effect: p < 0.001, [ηp2 = 0.613], and sex effect: p < 0.001, [ηp2 = 0.574]. (B) Periosteal bone surface (Ps.BS): 6 weeks: sex × genotype
interaction: p = 0.070, [ηp2 = 0.084]; genotypic effect: p < 0.001, [ηp2 = 0.619], and sex effect: p = 0.060, [ηp2 = 0.090]; 16 weeks: sex × genotype interaction:
p = 0.007, [ηp2 = 0.118]; genotypic effect: p < 0.001, [ηp2 = 0.590], and sex effect: p < 0.001, [ηp2 = 0.624]. (C) Endocortical bone surface (Es.BS): 6 weeks: sex
× genotype interaction: p = 0.343, [ηp2 = 0.024]; genotypic effect: p < 0.001, [ηp2 = 0.396], and sex effect: p = 0.319, [ηp2 = 0.026]; 16 weeks: sex × genotype
interaction: p = 0.013, [ηp2 = 0.101]; genotypic effect: p < 0.001, [ηp2 = 0.590], and sex effect: p < 0.001, [ηp2 = 0.635]. (D) Marrow area: 6 weeks: sex ×
genotype interaction: p = 0.157, [ηp2 = 0.052]; genotypic effect: p < 0.001, [ηp2 = 0.430], and sex effect: p = 0.238, [ηp2 = 0.036]; 16 weeks: sex × genotype
interaction: p = 0.002, [ηp2 = 0.157]; genotypic effect: p < 0.001, [ηp2 = 0.607], and sex effect: p < 0.001, [ηp2 = 0.467] in Dp1Tyb and control male and female
mice at 6 and 16 weeks. Significant differences and interactions for individual parameters are as determined by ANOVA and the p value is followed by partial eta
squared [ηp2] as a measure of effect size. Similarities and differences between individual groups are determined from Tukey's multiple comparisons post hoc tests;
values with the same superscript letter are not significantly different. Letters a,b,c,d are used for comparisons of 6 week old animals; letters e,f,g,h are used for
comparisons of 16 week old animals.
J.R. Thomas, et al. Bone 136 (2020) 115367
5
force (measuring general strength of bone), postyield work (energy
absorbed after permanent deformation), and total work (total energy
absorbed by the bone during bending). Male as compared to female 6-
week-old mice also showed a higher ultimate force. (Table 2 and Fig. 3).
At 16 weeks of age, the only sex × genotype interaction for extrinsic
bone properties was for ultimate force, with control males greater than
all other mice and Dp1Tyb males greater than Dp1Tyb females. Control
as compared to Dp1Tyb mice at 16 weeks of age had a higher postyield
displacement, stiffness, postyield work, and total work; and Dp1Tyb as
compared to control mice displayed higher values of displacement to
yield and work to yield. At 16 weeks of age, males as compared to
females had higher measurements for stiffness, postyield work, and
total work (Table 3 and Fig. 3). Taken together, these data indicate that
there was a strong genotypic effect at 6 weeks in extrinsic bone prop-
erties but at 16 weeks, sex and especially genotype had non-interactive
effects on overall bone properties. At 16 weeks of age, additional gene
dosage and female sex were detrimental to whole bone properties.
3.6. Dp1Tyb and female mice appear to have improved intrinsic bone
properties
At 6 weeks of age there were no effects in the intrinsic properties
(material properties independent of size and shape) of bone in Dp1Tyb
as compared to control or male as compared to female mice. At
16 weeks, control males had a lower modulus (stiffness of material)
than all other mice (sex × genotype interaction), and both female and
male Dp1Tyb mice had a higher modulus than their control littermates
(Table 3 and Fig. 3). Also at 16 weeks, bone from Dp1Tyb as compared
to control mice displayed a higher yield stress (normalized force to size
and shape of bone), ultimate stress, and resilience. Control as compared
to Dp1Tyb mice had a higher total strain. Female mice had marginally
increased yield stress as compared to male mice. Taken together, these
data indicate that at 16 weeks, Dp1Tyb and female mice seem to have
improved material bone properties as compared to control and male
mice, especially in the elastic region before the bone becomes perma-
nently deformed.
3.7. Histomorphometric analysis of cellular properties show sex effects in
Dp1Tyb and control mice
To understand more about the cellular properties of the femur at
16 weeks when sex and genotypic dimorphisms in intrinsic and ex-
trinsic properties are observed, we analyzed dynamic properties in both
cortical (femur midshaft) and trabecular (distal femur) bone. In addi-
tion, but not related to mechanical assessment, we analyzed static
properties in the trabecular bone of 16-week-old male and female
Dp1Tyb and control littermate mice. In cortical bone at the femoral
midshaft on the periosteal surface, male as compared to female mice
showed increased MS/BS (p < 0.001, percentage of bone undergoing
active formation, and an estimate of osteoblast activity), BFR
(p = 0.04, measure of the total rate of new bone formation on the
surface being mineralized) and MAR (p = 0.04, osteoblast vigor, the
rate at which osteoblasts lay down new bone matrix or osteoid)
(Fig. 4A–C). On the endocortical surface, male control as compared to
all other mice had a smaller MS/BS (p = 0.008) (sex × genotype in-
teraction). Male control as compared to all female mice had a smaller
BFR (p = 0.04) (sex × genotype interaction) (Fig. 4D–F). Taken to-
gether, these data support the notion that male mice are more active in
forming bone on the periosteal surface while female and trisomic mice
are more active in forming bone on the endocortical surface at 16 weeks
of age.
In the trabecular bone, there was an increase in female control as
compared to male control bone in MS/BS (p = 0.02) and BFR
(p = 0.02) (sex × genotype interaction) (Fig. 5A–C). Bone from female
Table 1
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as compared to male mice exhibited a higher trabecular MAR
(p = 0.02) at 16 weeks of age (Fig. 5C). Osteoid surface per bone
surface (OS/BS) (p = 0.04) and OS/BS percentage (p < 0.001) were
also greater in trabecular bone of female as compared to male mice.
Male Dp1Tyb mice had a lower osteoclast number on the bone surface
(Oc#/BS) as compared to all other mice at 16 weeks of age (sex ×
genotype interaction, p = 0.02) (Fig. 5D) as measured by Tartrate-re-
sistant acid phosphatase (TRAP) labeled multinucleated osteoclasts.
Additionally, the percentage of bone surface covered by osteoclasts
(OcS/BS) was significantly reduced in male as compared to female
(p = 0.004) and control as compared to Dp1Tyb (p = 0.0001) mice
(Fig. 5D).
When comparing only mice of the same sex, we observed a mar-
ginally increased trabecular osteoblast activity and vigor in 16-week-
old male Dp1Tyb male as compared to control mice (MS/BS: p = 0.04,
and BFR p = 0.10, 2 tailed t-test). In 16-week-old female mice, there
was a suggestive decrease in Dp1Tyb as compared to control mice in
trabecular MS/BS and BFR (p = 0.11 and p = 0.09, 2 tailed t-test).
There was reduced trabecular bone osteoclast surface and number in
the distal femur of male Dp1Tyb as compared to control littermates at
16 weeks of age (p < 0.001, 1 tailed t-test). In female mice at 16 weeks
there was a slight reduction in percent osteoclast number in Dp1Tyb as
compared to control animals (p = 0.06, 2 tailed t-test) and no differ-
ence in osteoclast surface between Dp1Tyb and control mice in trabe-
cular bone. No difference was found between male Dp1Tyb and control
mice in periosteal cortical MS/BS, MAR, or BFR; there was an increase
in Dp1Tyb endosteal MS/BS (p = 0.02, 2 tailed t-test) but no differ-
ences in endosteal MAR or BFR. There were no significant differences in
female periosteal or cortical MS/BS, MAR or BFR. Taken together, these
data suggest that in the distal femur at 16 weeks of age, control female
mice have the highest osteoblast activity, and Dp1Tyb male mice have
the lowest osteoclast activity.
4. Discussion
The novel examination of male and female mice in the Dp1Tyb
mouse model of DS during typical times of bone accrual and skeletal
maturity revealed the effect of both the sex of the mouse and the pre-
sence/absence of three copies of dosage sensitive genes on skeletal
phenotypes associated with DS. Here we report the first evidence of
sexual dimorphism in skeletal deficits of DS model mice that parallels
differences between skeletal deficits in humans with DS of different
sexes. The non-invasive quantification of bone deficits in humans with
DS gives insight into some parameters, including BMD, but does not
provide information on the geometry or composition of bone. BMD is a
metric used to calculate risk factor for fracture, however, many studies
do not include geometry, structural and strength indices that also affect
fracture incidence [37,48]. Until recently, studies of bone in individuals
with DS have often been done using small sample sizes that may have
not been able to detect important changes in bone between males and
females with DS during various developmental time points. Using
mouse models of DS allows for the quantification of structural, me-
chanical and cellular properties during different times of bone devel-
opment. The data obtained show clear age, sexual, and genotypic dif-
ferences in several measures that recapitulate many phenotypes
observed in individuals with DS, especially at formative developmental
stages.
At 6 weeks of age, trabecular parameters including BV/TV, Tb.Th,
Table 2

















n = 10 n = 10 n = 12 n = 10














































































































Values are averages (SEM). Similarities and differences between individual groups as determined from Tukey's multiple comparisons post hoc tests; values with the
same superscript letter are not significantly different. Data without letters within a single row are not significantly different from each other. Subject effects are p
values and partial eta squared (ηp2) in brackets.
J.R. Thomas, et al. Bone 136 (2020) 115367
7
Tb.N and Tb.Sp are adversely affected in both Dp1Tyb and wild-type
littermate female mice and are at similar levels as Dp1Tyb male mice.
Although females have reduced trabecular measures compared to male
wild-type mice at 6 weeks of age, trisomy does not further reduce those
measures. These data suggest a protective effect of female sex against
trisomic defects during longitudinal bone growth. As mice reach the age
of skeletal maturity at 16 weeks, BV/TV of female mice has not in-
creased; furthermore, Tb.N has decreased and Tb.Th and Tb.Sp have
increased in both Dp1Tyb and wild-type mice. In female mice, the re-
duction in Tb.N and increase in Tb.Sp may have negatively influenced
connectivity to the point that even with increased Tb.Th at 16 weeks,
skeletal measurements are still adversely affected. Taken together,
these results show that trisomy has little effect on the trabecular mi-
croarchitecture of female mice but could contribute to a decrease in
bone formation or an increase in resorption of trabeculae.
At 6 and 16 weeks, Dp1Tyb male and female mice generally have
deficits in cortical geometry as compared to their wild-type counter-
parts. The total CSA increased in male but not female mice from 6 to
16 weeks of age. Measures of cortical bone in male and female Dp1Tyb
mice are similar at 6 weeks. Female mice as a group do not have in-
creases of total CSA across ages, but exhibit decreases in marrow area
and an increase in cortical area. Dynamic histomorphometry of the
femoral midshaft suggests this increase is largely due to increased ac-
tivity of osteoblasts on the endocortical surface in female mice. Changes
in cortical geometry for control and Dp1Tyb mice in the cortical bone
follows a normal pattern of skeletal growth, with three copies of genes
enhancing deficits in female mice.
4.1. Similarities between humans with DS and DS mouse models
It is hypothesized that the osteoporotic phenotype found in in-
dividuals with DS is highly influenced by limited bone mineral
accretion and reduced peak bone mass attainment during adolescence
[11,30]. In humans the age of total body peak bone mass has been
estimated to be about 18.8 years in females and 20.5 years in males
[49]. Individuals with DS attain peak bone mass earlier and at lower
levels than normal individuals [11]. Women with DS (as well as normal
women) have bone mineral accrual later than men, but experience
rapid bone loss after the age of 40 [30]. Men with DS have a gradual
loss of bone after early adulthood, similar to men without DS, but the
rate of loss is increased in men with DS [14,30].
Information from the analyses described herein concentrated on
skeletal properties during bone accrual (6 weeks) until the estimated
age of skeletal maturity in mice (16 weeks) [50]. There are few studies
that have examined DS skeletal deficits in humans during adolescence
and the time of peak bone accrual, and the results from Dp1Tyb male
and female mice may help explain previous reports. The lower BMD
seen in adolescent males and females with DS analyzed together as
compared to normal individuals [25,26] compares to the genotype ef-
fect causing low BV/TV (and BMD) in 6-week Dp1Tyb mice. A study of
adolescents with DS that found no differences in BMD between males
and females [27] correlates to the similar BV/TV levels in 6 week old
male and female Dp1Tyb mice. At an age corresponding to skeletal
maturity in individuals with DS, both males and females had a lower
BMD [1], with DS females having a lower BMD than DS males in their
limbs [2]; both male and female Dp1Tyb mice had significantly affected
bone structure at 16 weeks, and trabecular and cortical values were
significantly lower in females than males at 16 weeks. The data pre-
sented herein also demonstrate that male Dp1Tyb mice exhibit osteo-
penic phenotypes earlier than their control counterparts, similar to
what has been observed in individuals with DS [14,28] and that os-
teoporotic phenotypes affect males as well as females in early adult
stages [30].
Fig. 3. Schematic representation of mechanical testing curves (data represented by mean ± SEM). A and B) Representations of force-displacement curves at the
structural level. C and D) Representations of stress-strain curves at the tissue level. S, is related to the stiffness or modulus of the femur. Y, the yield point represents
elastic behavior, indicating the bone's resistance to permanent deformation, past this point, U is the plastic region or permanent deformation where the bone has
sustained permanent damage.
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4.2. Comparison of Dp1Tyb and other DS model mice
Bone deficits associated with DS were first identified in Ts65Dn
male mice [36]. A comparison between these and previously published
results reveals similar direction and magnitude in trabecular, cortical
and mechanical deficits in mice that are at dosage imbalance for genes
homologous to Hsa21 [36,39]. Previous studies of 6, 12, 16 week, and
24 month old male mice found no significant differences in trabecular
thickness (Tb.Th) between Ts65Dn and euploid mice, though these
values were near a p < 0.05 significance level [36,37]. Tb.Th was
significantly different between Ts65Dn and control mice at 6 weeks of
age and was corrected in Ts65Dn,Dyrk1a+/- mice in a subsequent
study [39]. The differences in Tb.Th between Dp1Tyb and wild-type
mice seem to confirm the dissimilarities in the later study. The data
presented confirm that the Dp1Tyb DS mouse model is an effective
model for skeletal deficits in male and female DS model mice.
Male and female Ts1Rhr mice, containing 33 triplicated genes, at 3
and 16 weeks have been examined for bone deficits associated with DS
[42]. At 3 weeks (a developmental age prior to where we identified
differences in BV/TV at 6 weeks in Dp1Tyb and control littermate fe-
male mice), BMD was not statistically different between male or female
Ts1Rhr or control mice. It may be that BMD is not significant between
Ts1Rhr and control male mice at this pre-pubertal age. At 16 weeks, in
Ts1Rhr and littermate control mice, areal BMD was not significantly
different in the femur, but was decreased in the tibia and increased in
the spine. Our analyses of femoral bone in Dp1Tyb and littermate mice
found significantly different trabecular BMD between both male and
female mice at 16 weeks of age. Further studies, including microCT,
were not performed on the bones of Ts1Rhr and control littermate mice,
and given the analyses included herein, we hypothesize that other
structural and mechanical bone abnormalities exist between Ts1Rhr
and control mice. Conversely, the reduction in genes at dosage im-
balance in Ts1Rhr as compared to Dp1Tyb mice could dilute any po-
tential effect from triplicated genes.
Differences between skeletal abnormalities could also be due to
genetic background, number and which genes are at dosage imbalance,
and origin of the change in genetic dosage. Differences in skeletal
phenotypes could be due to differences in triplicated gene content or
genetic background of Ts65Dn (104 genes, ~50% B6 and ~50% C3H)
and Dp1Tyb (148 genes, 100% B6) and Ts1Rhr (33 genes, 100% B6)
mice. Differences in trisomy may also contribute to skeletal differences
between mouse models. Ts65Dn has a freely segregating extra chro-
mosome with the telomeric end of Mmu16 attached to the centromeric
end of Mmu17. This includes ~35 protein-coding genes at dosage im-
balance from Mmu17 that are not homologous to Hsa21 [32,40,41].
Both Dp1Tyb and Ts1Rhr mice have a duplication of parts of the distal
end of Mmu16 and do not have a freely segregating trisomic chromo-
some. All of these factors may lead to differences between the DS mouse
models that have been used to detect skeletal abnormalities associated
with DS. We note that as the gene content of Dp1Tyb mice is known, it
may now be possible to look for the causal genes for bone defects, i.e.
those sequences on Hsa21 that have an effect when present in three
copies.
4.3. Mechanical properties of Dp1Tyb mice
Bone is hierarchical and alterations in bone composition, archi-
tecture, and cellular activity can increase or decrease bone strength.
Our results suggest changes in trabecular microarchitecture and cortical
geometry also affected mechanical properties. At 6 weeks of age, most
of the significant differences between Dp1Tyb and control mice were
found in whole bone properties. In general, control and male mice at 6
and 16 weeks had stronger bones or greater resistance to bending and
catastrophic failure compared to their Dp1Tyb counterparts. Genetic
dosage imbalance could be sufficient to cause alterations in the devel-
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At 16 weeks enhanced effects on bone tissue, independent of bone
size and shape, were observed. Female as compared to male mice dis-
played an increase in yield stress but had marginally lower toughness.
These increases in material properties of bone in Dp1Tyb mice may
indicate brittle bones that are more prone to fracture. Dp1Tyb mice
showed an increase in yield properties in both the load-displacement
and stress-strain curves. Increases in yield properties are related to bone
mineral content and post-yield properties associated with collagen.
Dp1Tyb mice had lower toughness, post yield work and total work,
suggesting they absorbed less energy prior to fracture and possibly
fracture sooner than control animals.
4.4. Cellular deficits in mouse models of DS
Quantification of cellular composition in trabecular and cortical
bone in 6-week-old male Ts65Dn as compared to control mice showed
reduced osteoblast number and/or activity coupled with increased os-
teoclast activity caused the DS like skeletal deficits at that age [36,39].
A low bone turnover hypothesis was proposed for the deficits skeletal
deficits seen in 12-week-old male Ts65Dn mice because of decreased
osteoclast and osteoblast activity found on proximal tibia and femur as
compared to euploid mice at this age [37]. In 16-week-old male mice,
we observed increased osteoblast activity and reduced osteoclast
number and activity in the trabecular compartment of Dp1Tyb as
compared to control mice. In female mice of the same age, there was a
decrease in Dp1Tyb osteoblast activity. These results indicate that os-
teoblast and osteoclast activity was different in 16-week-old male
Dp1Tyb mice than previously reported osteoblast and osteoclast ac-
tivity in Ts65Dn mice at 6 and 12 weeks. Only a slight increase in os-
teoblast activity on the periosteal surface of male Dp1Tyb cortical bone
was observed. Taken together, these data suggest that sex, gene dosage,
bone location and age are all important in the cellular components
Dp1Tyb as compared to control mice. Furthermore, the cellular me-
chanisms leading to bone deficits associated with DS may be distinct at
different points in development.
These data demonstrate fundamental differences in skeletal devel-
opment between Dp1Tyb and wild-type mice. For the first time, they
also indicate clear sexual dimorphisms in the development of DS mouse
model bone and illustrate time-dependent nature of developmental
differences in the DS-associated skeletal deficits. Similarities between
the abnormalities in humans with DS and Dp1Tyb mice suggest that
skeletal defects result from conserved mechanisms. Sexual dimorph-
isms, gene dosage, age and bone compartments are all influential in
causing alterations in developmental properties that lead to the unique
skeletal differences caused by trisomy. These results will help to better
understand how trisomy affects individuals with DS and determine
which measures may prevent adverse skeletal phenotypes. Additional
research is needed to determine when sex-specific skeletal abnormal-
ities develop, how interactions between trisomy and sex influence
specific skeletal alterations, and the influence of sex and trisomy on the
cellular mechanisms related to these changes in bone development.
Fig. 4. Dynamic bone labeling measures of the cortical region of Dp1Tyb and control femurs at 16 weeks of age (data represented by mean ± SEM). (A) Periosteal
mineralizing surface/bone surface (MS/BS), (B) Periosteal mineral apposition rate (MAR), (C) Periosteal bone formation rate (BFR), (D) Endocortical MS/BS, (E)
Endocortical MAR, (F) Endocortical BFR. In (B) and (C), there were no measurable effects in female control MAR and BFR (9 samples in each group). Similarities and
differences between individual groups are determined from Tukey's multiple comparisons post hoc tests; values with the same superscript letter are not significantly
different. Letters a,b,c,d are used for comparisons of 6 week old animals; letters e,f,g,h are used for comparisons of 16 week old animals.
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comparisons post hoc tests; values with the same superscript letter are not significantly different. Letters a,b,c,d are used for comparisons of 6 week old animals;
letters e,f,g,h are used for comparisons of 16 week old animals.
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